Federica Pecci
@pecci_federica1
Research Fellow at @DanaFarber Thoracic Oncology
ID: 1465357708018827268
29-11-2021 16:31:27
117 Tweet
362 Followers
453 Following
🚨Out in JAMA Oncology our effort to determine the association of automatically extracted body composition metrics with #immunotherapy efficacy in patients with metastatic #NSCLC. 👉Skeletal muscle loss & changes in subcutaneous adipose tissue are important dynamic prognostic
The association of automatically extracted body composition metrics with IO efficacy in mNSCLC - Biagio Ricciuti, MD PhD JAMA Oncology Dana-Farber News Tafadzwa L. Chaunzwa João Alessi, MD Alessandro Di Federico, MD Mark Awad oncodaily.com/insight/73659.… #Cancer #CancerResearch #LCSM #NSCLC #OncoDaily #Oncology
Excellent #ASCO24 with colleagues and friends. Proud to be part of both Gustave Roussy and Dana-Farber Thanks to my mentors Benjamin Besse Mark Awad
Couldn’t agree more!! Arushi is talented and compassionate med student. Her work will be instrumental to understanding the correlates of response to #immunotherapy in #NSCLC with STK11/KEAP1/SMARCA4 mutations. Harvard Medical School Dana-Farber. More on this at #WCLC24 IASLC.
Thanks Annals of Oncology for featuring our review on how to optimize the use of #TMB for predicting #ICI efficacy on this month’s cover. ESMO - Eur. Oncology Here we reviewed challenges & opportunities for TMB & immunotherapy focusing on: -Technical limitations 🔬 -Spatial & temporal
Thanks OncoAlert Narjust Florez, MD, FASCO for the opportunity to share our prospective study presented at Best of ASCO as poster presentation Luca Cantini Valeria Cognigni Mariangela Gualtieri Giulia Bruschi rossanaberardi
KEAP and STK11 mutations are a kind of defense mechanism. IO + chemo would be improve that response? Great paper 🔖 jto.org/action/showPdf… Congratulations! Biagio Ricciuti, MD PhD Marina Garassino
🚨Fusion partners and chromosomal breakpoints of oncogenic fusions involving #ALK, #ROS1, #RET and #NTRK1 are not stochastic! Out in Nature Communications our study demonstrating that typical #TK fusions are selected from pools of chromosomal rearrangements by two major determinants:
Honored to receive a 2024 IASLC #YIA. Congrats to all awardees & friends Biagio Ricciuti, MD PhD, Alessio Cortellini & others. 🌎Collaboration is key to help our patients. Thank you IASLC #LCSM #TeamScience Gustave Roussy Dana-Farber Benjamin Besse Mark Awad shorturl.at/Qo6SU
Congrats to my dear friends and collaborators Mihaela Aldea & Alessio Cortellini on receiving a 2024 IASLC #YIA. Echoing Mihaela Aldea, 🌍 collaboration is key to advancing the field and developing better treatments for #NSCLC.
Just published in Annals of Oncology our study investigating intrapatient variation in PD-L1 & TMB and the impact on outcomes to #immunotherapy in patients with #NSCLC 🧵1/9 Dana-Farber News Dana-Farber's Lowe Center for Thoracic Oncology ESMO - Eur. Oncology IASLC OncoAlert OncLive.com #LCSM annalsofoncology.org/article/S0923-…
The August issue of Cancer Discovery is now online! The cover features work by Federica Pecci, Seshiru Nakazawa, Pasi Janne, Mark Awad and colleagues showing that activating point mutations in MET are actionable in lung cancer - read that and more here: aacrjournals.org/cancerdiscover…
Just published in Annals of Oncology ESMO - Eur. Oncology our paper on intrapatient variation in PD-L1 and TMB in #NSCLC authors.elsevier.com/c/1jZPc3I2OQih… Jim Smithy Biagio Ricciuti, MD PhD João Alessi, MD Federica Pecci Mark Awad
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of #LungCancer and Other Malignancies Targetable with MET Inhibitors. bit.ly/4cFiu18 Federica Pecci, Seshiru Nakazawa, Pasi Janne, Mark Awad and colleagues. Dana-Farber
Just out on ESMO Open: #MET exon 14 skipping mutations in #NSCLC #RWD from the Italian biomarker ATLAS database Biomarkers Atlas Great network of colleagues and friends Giulia pasello Francesco Umberto Malapelle Marcello Tiseo sciencedirect.com/science/articl…